>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:
  • WMIH +63.3%, GNC +36%, TYHT +29%, DAC +15.4%, UAA +12.4%, RNG +9.2%, QTNA+8.5%, WB +7.1%, VIPS +6.8%, APRN +6.3%, SREV +6.1%, (signs multi-year contract extensions with two long-standing technology clients), VECO +4.6%, DBD +4.5%, VRNS+3.9%, QLYS +3.4%, CHGG +3.3%, NRZ +3.2%, SQNS +2.6%, DNB +2.1%, FMC +2%, AMKR+1.3%, BRX +1.2%, ONDK +1.1%, AB +1%
M&A news:
  • CRVP +22.2% (Cott announces agreement to acquire Crystal Rock Holdings for approx $35 mln)
  • ABC +12.3% (AmerisourceBergen: Walgreens (WBA) has made an offer to acquire ABC, according to WSJ)
  • HDNG +8.3% (Hardinge to be acquired by Privet Fund Management for $18.50 per share in cash)
Other news:
  • VRTX +3.3% (announces FDA approval of FDA SYMDEKO to treat the underlying cause of Cystic Fibrosis in people ages 12 and older with certain mutations in the CFTR gene-to begin shipping to pharmacies this week)
  • CBIO +2.9% (announces proposed public offering of common stock)
  • DNR +2.9% (reports Q4 production was 61,144 barrels of oil equivalent per day; 2018 development capital budget is $300-325 million)
  • CLLS +2.6% (granted 2 patents for CRISPR Use in T-Cells in the US)
  • GRA +0.6% (CEO/Chairman discloses the purchase of 25k shares)
Analyst comments:
  • CBAY +6.1% (initiated with a Outperform at Evercore ISI)
  • ICHR +4.6% (upgraded to Strong Buy from Buy at Needham)
  • ADT +4.1% (initiated with a Buy at Goldman, among others)
  • NTAP +3% (upgraded to Buy from Neutral at BofA/Merrill; upgraded to Buy from Hold at Loop Capital)
  • ADI +1.7% (upgraded to Overweight from Neutral at Piper Jaffray)
  • NINE +1.7% (initiated with a Overweight at JP Morgan; initiated with a Buy at BofA/Merrill)
  • FRAC +1.4% (upgraded to Buy from Neutral at Citigroup)
  • HIIQ +1.1% (initiated with a Buy at B. Riley FBR)
  • CELG +1% (upgraded to Overweight from Equal Weight at Barclays)
  • MMM +0.9% (upgraded to Buy from Hold at Deutsche Bank)
  • TOT +0.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley; upgraded to Strong Buy at Raymond James)